BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

958 related articles for article (PubMed ID: 31955850)

  • 1. Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery.
    Burslem GM; Crews CM
    Cell; 2020 Apr; 181(1):102-114. PubMed ID: 31955850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
    Pettersson M; Crews CM
    Drug Discov Today Technol; 2019 Apr; 31():15-27. PubMed ID: 31200855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
    Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
    Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of ubiquitin ligases in the PROTAC drug design.
    Chen Y; Jin J
    Acta Biochim Biophys Sin (Shanghai); 2020 Jul; 52(7):776-790. PubMed ID: 32506133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo synthetic chemistry of proteolysis targeting chimeras (PROTACs).
    Tomoshige S; Ishikawa M
    Bioorg Med Chem; 2021 Jul; 41():116221. PubMed ID: 34034148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies.
    Wu Y; Zhang J; Zhu X; Zhang Y
    Cancer Lett; 2022 Sep; 544():215808. PubMed ID: 35764266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PROTAC-DB: an online database of PROTACs.
    Weng G; Shen C; Cao D; Gao J; Dong X; He Q; Yang B; Li D; Wu J; Hou T
    Nucleic Acids Res; 2021 Jan; 49(D1):D1381-D1387. PubMed ID: 33010159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolysis targeting chimeras (PROTACs) for epigenetics research.
    Vogelmann A; Robaa D; Sippl W; Jung M
    Curr Opin Chem Biol; 2020 Aug; 57():8-16. PubMed ID: 32146413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early evaluation of opportunities in oral delivery of PROTACs to overcome their molecular challenges.
    Yang W; Saboo S; Zhou L; Askin S; Bak A
    Drug Discov Today; 2024 Feb; 29(2):103865. PubMed ID: 38154757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications.
    Li Q; Zhou L; Qin S; Huang Z; Li B; Liu R; Yang M; Nice EC; Zhu H; Huang C
    Eur J Med Chem; 2023 Sep; 257():115447. PubMed ID: 37229829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PROTACs: New method to degrade transcription regulating proteins.
    Hu B; Zhou Y; Sun D; Yang Y; Liu Y; Li X; Li H; Chen L
    Eur J Med Chem; 2020 Dec; 207():112698. PubMed ID: 32858471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
    Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
    BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
    Li R; Liu M; Yang Z; Li J; Gao Y; Tan R
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frontiers in PROTACs.
    Hughes GR; Dudey AP; Hemmings AM; Chantry A
    Drug Discov Today; 2021 Oct; 26(10):2377-2383. PubMed ID: 33872800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PROTAC-induced proteolytic targeting.
    Carmony KC; Kim KB
    Methods Mol Biol; 2012; 832():627-38. PubMed ID: 22350917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rise of covalent proteolysis targeting chimeras.
    Gabizon R; London N
    Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target Validation Using PROTACs: Applying the Four Pillars Framework.
    Nowak RP; Jones LH
    SLAS Discov; 2021 Apr; 26(4):474-483. PubMed ID: 33334221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.